- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06716242
첫 번째 및 두 번째 삼 분기의 조기/후기 자간전증 선별을 위한 MaiRa 자간전증 테스트의 검증 (iPregnostic)
자간전증의 조기 발견을 위한 분자 선별검사의 성능을 확인하기 위한 전향적, 관찰적, 다기관 연구
Preeclampsia (PE) is a major obstetric complication with severe short- and long-term consequences for both mother and fetus. Early detection is critical to mitigate PE-related morbidity and mortality. Effective screening tools are needed to identify women at risk, enabling timely preventive and therapeutic interventions.
Current screening methods primarily target placental biomarkers like sFLT1 and PlGF, which are limited to short-term predictions near symptom onset. Existing first-trimester assessments that incorporate maternal factors and Doppler metrics remain constrained by low sensitivity (<41%) in compliance with NICE and ACOG guidelines.
Recent advancements in cell free RNA (cf-RNA) analysis have revealed potential in first-trimester PE prediction. Findings from the PREMOM study (NCT04990141) established a molecular profile for early-onset preeclampsia (EOPE) and late-onset preeclampsia (LOPE) through cfRNA analysis, culminating in the development of the MaiRa Preeclampsia Test (Maternal Advanced and Innovative Preeclampsia Risk Assessment), which demonstrated high predictive performance for first- and second-trimester screening.
The current study hypothesizes that the MaiRa Preeclampsia Test is generalizable, maintaining its predictive accuracy in an independent cohort.
연구 개요
상세 설명
This multicentre, prospective observational study aims to validate the MaiRa Preeclampsia Test, a molecular screening tool for predicting early-onset preeclampsia (EOPE) and late-onset preeclampsia (LOPE) in the first and second trimesters of pregnancy. The study will evaluate its diagnostic accuracy, including sensitivity, specificity, predictive values, and area under the curve (AUC).
Study Design:
Duration: 40 months
- Recruitment and Sample Collection: 28 months
- Sample Analysis: 32 months
- Follow-Up: 8 months
- Statistical Analysis and Publication: 6 months Participants: 7,473 pregnant women from 12 tertiary hospitals in Spain.
Visits:
- Visit 1 (T1): 9-14 weeks' gestation (first blood sample)
- Visit 2 (T2): 15-26 weeks' gestation (second blood sample)
- Visit 3 (T3): ≥27 weeks' gestation (third blood sample)
Blood samples will be analyzed using the MaiRa Preeclampsia Test, with results correlated against obstetric outcomes as the gold standard. Data will be documented in an electronic Case Report Form (eCRF). Quality assurance will be maintained via continuous data monitoring and verification.
연구 유형
등록 (추정된)
연락처 및 위치
연구 장소
-
-
Alicante
-
Alicante, Alicante, 스페인, 03010
- Hospital General Universitario Dr. Balmis
-
-
Barcelona
-
Barcelona, Barcelona, 스페인, 08025
- Hospital de la Santa Creu i Sant Pau
-
-
Castellón
-
Vinaròs, Castellón, 스페인, 12500
- Hospital Comarcal de Vinaròs
-
-
Cádiz
-
Cadiz, Cádiz, 스페인, 11009
- Hospital Universitario Puerta del Mar
-
-
La Coruña
-
A Coruña, La Coruña, 스페인, 15006
- Hospital Universitario A Coruña
-
-
Madrid
-
Torrejón de Ardoz, Madrid, 스페인, 28850
- Hospital Universitario de Torrejón
-
-
Murcia
-
El Palmar, Murcia, 스페인, 30120
- Hospital Clínico Universitario Virgen de la Arrixaca
-
-
Santa Cruz de Tenerife
-
San Cristóbal de La Laguna, Santa Cruz de Tenerife, 스페인, 38320
- Hospital Universitario de Canarias
-
-
Valencia
-
Manises, Valencia, 스페인, 46940
- Hospital de Manises
-
Valencia, Valencia, 스페인, 46017
- Hospital Universitario Doctor Peset
-
Valencia, Valencia, 스페인, 46026
- Hospital Universitario y Politécnico La Fe
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
Pregnant patients aged 18 years or older, recruited between 9 and 14 weeks' gestation during routine obstetrical follow-ups at referral hospitals.
설명
Inclusion Criteria:
- Signed informed consent approved by the Ethics Committee.
- Women ≥18 years of age at consent.
- Single gestation pregnancies with first sample collection (T1) possible between 9 and 14 weeks' gestation.
Exclusion Criteria:
- Active neoplasm.
- History of organ or bone marrow transplantation.
- Maternal transfusion within 8 weeks before sample collection.
- Evidence of early pregnancy loss at consent.
- Severe, uncontrolled infections.
- Other investigator-assessed risks that could compromise participation or data quality.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: COHORT
- 시간 관점: PROSPECTIVE
코호트 및 개입
그룹/코호트 |
개입 / 치료 |
|---|---|
|
Pregnant patients aged 18 years or older
Pregnant patients aged 18 years or older recruited between 9 and 14 weeks' gestation during routine obstetrical follow-ups at referral hospitals. |
Maternal peripheral blood will be collected 3 times during pregnancy (1st, 2nd and 3rd trimester) and clinical data will also be compiled. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Validation of the MaiRa Preeclampsia Test for first-trimester screening (9-14 weeks) of EOPE
기간: From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks.
|
Sensitivity, specificity, accuracy, F1-score, positive/negative predictive values, false discovery rate, AUC. |
From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks.
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Validation of second-trimester screening (15-26 weeks) for EOPE
기간: From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks.
|
Sensitivity, specificity, accuracy, F1-score, positive/negative predictive values, false discovery rate, AUC. |
From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks.
|
|
Validation of second-trimester screening (15-26 weeks) for LOPE
기간: From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks.
|
Sensitivity, specificity, accuracy, F1-score, positive/negative predictive values, false discovery rate, AUC. |
From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks.
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Exploratory outcome: Validation of first-trimester screening (9-14 weeks) for LOPE
기간: From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks.
|
Sensitivity, specificity, accuracy, F1-score, positive/negative predictive values, false discovery rate, AUC. |
From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks.
|
|
Exploratory outcome: Validation of first and second trimester screening for other pregnancy complications
기간: From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks.
|
Other pregnancy complications such as preterm labour, intrauterine growth restriction, gestational diabetes and placenta previa among others. Sensitivity, specificity, accuracy, F1-score, positive/negative predictive values, false discovery rate, AUC. |
From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks.
|
|
Exploratory outcome: Molecular characterization of cfRNA and other biomarkers across gestation
기간: From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks.
|
DNA/RNA/proteins/metabolites associated with gestational age and clinical outcomes. |
From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks.
|
|
Exploratory outcome: Identification of candidate biomarkers in maternal blood for therapeutic interventions
기간: From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks.
|
Molecular characterization (DNA/RNA/proteins/metabolites). |
From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks.
|
공동 작업자 및 조사자
스폰서
수사관
- 수석 연구원: Carlos Simón, MD, PhD, Carlos Simon Foundation
- 수석 연구원: Tamara Garrido, PhD, iPremom
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- IPR-IPR-TG-24-01
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .